Best Fit Profiles
- AMD prevention and macular pigment support, particularly in low-carotenoid diets
Macular pigment and eye health
Zeaxanthin
Zeaxanthin is a xanthophyll carotenoid concentrated in the fovea of the macula. AREDS2 demonstrated that lutein + zeaxanthin reduces AMD progression in high-risk individuals. Dietary intake from leafy greens is the primary source.
Evidence Level A
Evidence and Risk Labels
Evidence A/B/C reflects research maturity, and risk levels reflect monitoring needs. These labels support comparison, not diagnosis or treatment decisions.
See full scoring guideClinical Snapshot
- Effect Size
- Meaningful reduction in AMD progression risk in high-risk populations; moderate macular pigment density improvement
- Safety
- Low Risk
Minimal safety concerns at studied doses. Generally combined with lutein (10 mg lutein : 2 mg zeaxanthin per AREDS2 protocol).
Research Dosing
This reflects common ranges and protocols used in published studies, not personal medical advice.
- Typical Daily Dose
- 2 mg (as part of AREDS2 formula with 10 mg lutein)
- Timing
- With a fat-containing meal
- Protocol Duration in Studies
- Long-term for AMD prevention
Rarely found alone — typically combined with lutein in eye-health formulations.